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ABSTRACT 
 
Introduction and objective: Etelcalcetide is a novel intravenous calcimimetic for the 
treatment of secondary hyperparathyroidism (SHPT) in haemodialysis patients. The 
clinical efficacy and safety of etelcalcetide (in addition to phosphate binders and vitamin D 
and/or analogs; PB/VD) was evaluated in three phase 3 studies, including two placebo-
controlled trials and a head-to-head study versus the oral calcimimetic cinacalcet. The 
objective of this study was to develop a decision-analytic model for economic evaluation of 
etelcalcetide compared to cinacalcet. 
Methods: We developed a life time Markov model including potential treatment effects on 
mortality, cardiovascular events, fractures, and subjects’ persistence. Long term efficacy of 
etelcalcetide was extrapolated from the reduction in parathyroid hormone (PTH) in the 
phase 3 trials and the available data for outcomes study in cinacalcet (EVOLVE trial). 
Etelcalcetide was compared to cinacalcet, both in addition to PB/VD. We applied unit costs 
averaged from five European countries and a range of potential pricing options assuming 
parity price to weekly use of cinacalcet and varying it 15% or 30% higher.  
Results: Compared with cinacalcet, the incremental cost-effectiveness ratio of etelcalcetide 
was €1.355 per QALY, €24,521 per QALY and €47,687 per QALY for the three prices 
explored. The results were robust across the probabilistic and deterministic sensitivity 
analyses. 
Conclusions: Our modelling approach enables cost utility assessment of the novel therapy 
for SHPT based on the observed and extrapolated data. This model can be used for local 
adaptations in the context of reimbursement assessment.  
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KEY POINTS FOR DECISION MAKERS 
 While no hard outcomes data are available for etelcalcetide, its superior efficacy in 
reducing parathyroid hormone, compared to the oral calcimimetic cinacalcet, 
enables extrapolation to improved rate of survival, cardiovascular events, fractures 
and parathyroidectomy. 
 We provide a model which can be used to assess the cost-effectiveness of 
etelcalcetide compared to cinacalcet, both in addition to phosphate binders and 
vitamin D analogs. 
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1 Introduction and objective 
Secondary hyperparathyroidism (SHPT) is a disease characterized by the excessive 
secretion of parathyroid hormone (PTH) and associated with hyperplasia of the 
parathyroid glands. This disorder is a common complication in patients with chronic 
kidney disease (CKD) on haemodialysis. SHPT is linked to the risk of extra skeletal 
calcification, reduced bone density and strength [1], bone fractures [2] morbidity and 
mortality [3,4,5]. The prevalence of SHPT within dialysis population ranges between 30%-
49% in Europe and Australia and is estimated at about 54% in North America. [6]  
 
The traditional treatment of SHPT includes treatment with active forms of vitamin D or its 
analogs and phosphate binders. In the past years, cinacalcet, the first calcimimetic agent, 
has been established as an additional effective therapy for this indication. For patients with 
severe SHPT who fail to respond adequately to medical therapy, surgical removal of 
parathyroid glands (parathyroidectomy) is also a viable option. The National Kidney 
Foundation through its Kidney Disease Outcomes Quality Initiative (K/DOQI) has 
established clinical practice guidelines for bone metabolism and disease in CKD. These 
clinical practice guidelines also specify target levels of PTH, serum calcium, and serum 
phosphorus [7]. 
 
Etelcalcetide is a novel D-amino peptide calcimimetic approved in the EU and US for the 
treatment of SHPT in adult haemodialysis patients. Etelcalcetide is administered 
intravenously three times per week at the end of each dialysis session. This route of 
administration, from the patient perspective, has been shown to be more convenient 
(preferred) over an oral drug8. Etelcalcetide is an allosteric activator that binds to, and 
activates, the calcium-sensing receptors in the parathyroid gland, resulting in reduced PTH 
secretion. The efficacy of etelcalcetide in reducing PTH levels has been established  by three 
Phase 3 studies, two parallel placebo-controlled trials [9], and a head-to-head study 
comparing etelcalcetide to cinacalcet [10]. In the head-to-head study, etelcalcetide met the 
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primary endpoint of non-inferiority measured as the proportion of patients achieving a 
greater than 30% PTH reduction from baseline during the efficacy assessment phase, and 
the secondary endpoints of superiority (>50% and >30% reduction in PTH).  
 
The objective of this study was to develop a decision-analytic model for economic 
evaluation of etelcalcetide compared to cinacalcet. We expect that this model can be 
adapted to local settings and will be applied to inform reimbursement decisions.  
 
2 Methods 
We developed a Markov cohort state transition model using a 3-month cycle length, and a 
life-time horizon. . We followed the current best practice modelling and reporting 
guidelines [11,12] and considered previously published cinacalcet cost-effectiveness models 
as a context [13, 14]. We conducted model validation based on the AdViSHE validation tool 
(see electronic supplementary material) [15]. Furthermore, we applied a life-table half-cycle 
correction [16, 17]. Both costs and outcomes were discounted at an annual rate of 3%. 
Treatment with etelcalcetide was compared to cinacalcet. Both calcimimetics were 
assumed to be administered in addition to phosphate binders and vitamin D,or its analogs 
(PB/VD). As an option, we explored the comparison of etelcalcetide to ‘no calcimimetics’ 
(i.e. PB/VD alone) which would represent a clinical decision to use etelcalcetide after 
cinacalcet discontinuation (see electronic supplementary material). The characteristics of 
the model population were aligned with etelcalcetide trials [9,10] and the ‘EValuation Of 
Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events’ (EVOLVE) trial 
[18]. EVOLVE was a global, multi-center, placebo-controlled, double-blind, event-driven 
trial, that assessed the impact of cinacalcet on outcomes in an SHPT dialysis population [18]. 
The primary endpoint was a composite of all-cause mortality and major cardiovascular 
(CV) events. Other clinical events such as fractures and parathyroidectomy (PTx) were 
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registered as secondary endpoints [18, 19]. EVOLVE is the only long-term randomized 
clinical trial that directly measured the impact of calcimimetics on SHPT clinical outcomes. 
 
The design of the model is depicted in Figure 1. Simulated subjects enter the model in the 
“Event free” state. During the simulation, the subjects can experience CV events and 
fractures as a consequence of the disease, or die. Subjects who do not persist with 
calcimimetic treatment switch to PB/VD alone. Lastly, the occurrence of PTx was simulated 
as this event can generate costs and short-term health consequences. 
 
The decision model compares long-term outcomes (survival and quality-adjusted life-
years, QALYs) and overall costs. Calcimimetic treatment results in more controlled levels of 
SHPT biomarkers (PTH, serum calcium, and phosphorus), which are related to mortality as 
well as the incidence of CV events, fractures and PTx. The efficacy compared with ‘no 
calcimimetic treatment’ was parameterized as a hazard ratio (HR) by type of event (i.e. all-
cause mortality, non-fatal CV events, fractures and PTx). Rates of clinical events, while on 
calcimimetic treatment, were obtained by applying HRs to the baseline rates (no 
calcimimetic treatment) (Table 1) [18,20].  
 
The HRs for cinacalcet compared to ‘no calcimimetics’ were derived from EVOLVE [18] 
based on the event- specific HRs published by Belozeroff et al. [13]. Among the reported 
HRs, the lag-censored estimates (6-months lag) were most consistent with our model 
structure. This is, because both the model structure and the censoring approach distinguish 
between subjects on vs. off treatment. The EVOLVE pre-specified 6-month lag in the 
referenced source accounts for the delay between the drug intake and the treatment effect. 
As a sensitivity analysis to using lag-censored hazard ratios, we presented an intention-to-
treat (ITT)-based approach (see electronic supplementary material).  
 
No study is available that measured the incidence of clinical events in SHPT patients 
treated with etelcalcetide. Therefore, the cinacalcet efficacy has been extrapolated based on 
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the ability to lower PTH (see electronic supplementary material). The extrapolation was 
used separately for each type of event (i.e. mortality, CV events, fractures and PTx), and 
was based on the primary outcome of the etelcalcetide trial (i.e. the ability of the treatment 
to achieve a PTH reduction of at least 30% compared to baseline). More specifically, the 
proportion of subjects achieving the 30% PTH reduction was calculated separately for each 
treatment arm (etelcalcetide, cinacalcet, and placebo) across three etelcalcetide trials. 
Because the HR for cinacalcet is known for each event type, we used placebo as a reference 
and applied the share of subjects that met the primary endpoint to approximate the efficacy 
of etelcalcetide. 
 
The treatment effect in the model is applied as long as subjects persist on the calcimimetic 
treatments. As soon as subjects discontinue, the baseline incidence rates are applied. As a 
consequence, on a population basis, the treatment effect of the calcimimetic treatment 
fades out continuously. 
 
We modelled discontinuation with a parametric Weibull function (see electronic 
supplementary material). For the base case, we used the United States (US) real world data 
[21]. To test the sensitivity of the model to persistence assumptions, we applied EVOLVE 
trial persistence as an upper bound, and the lowest observed real-world persistence in 
Europe as a lower bound (one-year persistence: EVOLVE 73%, US 27%, France 27%, 
Germany 22%, Italy 16%). Given that no significant persistent difference (p=0.60) was 
observed within the head-to-head trial, the same discontinuation probabilities were 
applied for both calcimimetics. 
 
The utility values (EQ-5D, Dolan algorithm) for each of the health states in the model were 
derived from a published EVOLVE analysis [22] using separate estimates for ‘myocardial 
infarction’, ‘hospitalization for unstable angina’, ‘heart failure’ and ‘peripheral vascular 
event’. To derive a combined utility estimate for CV events, the number of events in 
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EVOLVE were used for weighting. The corresponding standard error was derived via error 
propagation [23].  
 
The cost perspective of the third-party payer was applied; the total cost was estimated as 
the sum of drug consumption, management of clinical events, and routine monitoring. 
Dosing for calcimimetics was quantified based on the efficacy assessment phase of the 
head-to-head trial [10]. Consistent with the modelling approach from Garside et al. [14], the 
same background PB/VD drug usage was assumed for all treatment strategies (Table 2).  
 
To parameterize this generic cost-effectiveness model, we applied crude averages of 
published drug prices and event costs across five European countries (Italy, Spain, 
Portugal, Switzerland, Czech Republic) [24]. These illustrative costs refer to the year 2010. 
Three potential etelcalcetide pricing scenarios were illustrated: 1) same weekly 
calcimimetic drug cost (WCDC), 2) 15% higher WCDC (‘+15% WCDC’) and 3) 30% higher 
WCDC (‘+30% WCDC’). We used the weekly costs because the frequency of administration 
differs between calcimimetics. The ratio of average drug usage was taken for price 
calculation. 
 
To assess the robustness of the model, a distribution-based probabilistic sensitivity 
analysis was conducted with key parameters varied simultaneously in 1,000 replications. 
The parameters of the uncertainty distributions were based on the point estimate and the 
standard error or confidence interval. The uncertainty of the primary endpoint of the 
etelcalcetide trials was sampled via the bootstrap approach. Hazard ratios of the cinacalcet 
treatment effect based on the EVOLVE trial were sampled via the Log-normal distribution. 
Baseline event rates were sampled via the Gamma distribution. Persistence-adjustment 
and extrapolation of efficacy based on the primary endpoint in the etelcalcetide study was 
re-calculated for the sampled values. 
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The Gamma distribution was also applied to sample resource usage and costs. Utility 
decrements were sampled based on the Normal distribution, whereas absolute utility 
values were sampled based on the Beta distribution. The results of probabilistic sensitivity 
analysis were displayed as a scatter plot on the cost-effectiveness plane and as cost-
effectiveness acceptability curves. 
 
We conducted a deterministic sensitivity analysis (DSA), where parameters were varied to 
the upper and lower bound of their 95% confidence intervals. For grouped parameters, or 
parameters without available standard errors (i.e. age-specific mortality, utility 
decrements, event costs, monitoring costs), plus/minus 20% of the point estimate were 
applied. The results of the DSA were displayed via a tornado diagram. 
 
We performed structural sensitivity analyses including a different approach to estimate the 
treatment effect (i.e. ITT hazard ratios), and different sources to quantify discontinuation. 
Lastly, to assess the uncertainty due to PTx, we included a scenario where the PTx 
incidence rate has been set to zero.  
 
3 Results  
Lifetime total costs and outcomes by treatment are reported in Table 3. Etelcalcetide was 
more effective, providing 0.032 additional discounted QALYs compared with cinacalcet. 
This limited QALY gain reflects the high calcimimetic discontinuation rate. If the weekly 
calcimimetics treatment costs were kept constant, the increased life-expectancy resulted in 
a cost increase of €49. If a price mark-up was allowed, a 30% cost increase, combined with 
the effect of increased life-expectancy, resulted in additional costs of €1,518 compared 
with cinacalcet. These incremental costs are based on the assumption that no additional 
administration costs are associated with etelcalcetide treatment. (Table 3) 
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Compared with cinacalcet, the incremental cost-effectiveness ratio (ICER) of etelcalcetide 
was €1,355 per QALY, €24,521 per QALY and €47,687 per QALY for the three pricing 
options explored.  
 
In the probabilistic sensitivity analysis, etelcalcetide consistently yielded more QALYs than 
cinacalcet (Figure 2).  
 
The tornado plot of the DSA is displayed in Figure 3 (for illustration purposes based on an 
increase of 15% of weekly calcimimetic treatment costs). The parameters with the highest 
impact on the ICER were the calcimimetic doses and the HR (etelcalcetide vs. cinacalcet) to 
reduce mortality. The order of these variables varied by pricing assumption. Other inputs 
with a high impact on the outcomes were the HRs on CV events, fractures, and PTx. 
 
The results of the structural sensitivity analyses are displayed in Table 4. A higher 
persistence led to increased ICERs. This is because at the later stages of the Markov model 
the treatment costs were equal, but the expected QALYs gained per event avoided 
decreased. When setting the PTx rate to zero, the ICER slightly increased. Incorporating ITT 
efficacy into the model resulted in a higher ability of etelcalcetide to reduce events. This is 
because of the implicit assignment of the spill-over treatment effect post discontinuation to 
the treatment period. For the +15% and the +30% treatment scenarios this resulted in 
slightly improved ICERs.  For the pricing scenario where the weekly calcimimetic treatment 
costs do not differ between calcimimetics, the reduced mortality shifts people into later 
life-time cycles, where at similar costs to avoid one event, the QALYs per event avoided 
decreases, resulting in a slight increase of the ICER. 
4 Discussion and conclusions 
We developed a model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. The 
rationale for selecting cinacalcet as the comparator was that in most settings it 
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corresponds to the current standard of care. The purpose of this article was not to calculate 
the cost-effectiveness of etelcalcetide itself. Neither did we intend to calculate for a given 
price and a given willingness-to-pay (WTP) threshold, how effective etelcalcetide would 
have to be. 
 
The efficacy of cinacalcet was directly based on the hard outcome trial EVOLVE. In contrast, 
though based on a randomized trial, the efficacy of etelcalcetide was extrapolated via a 
surrogate parameter. No hard outcomes study directly comparing etelcalcetide to 
cinacalcet exists, nor is there any observational studies as the therapy is just entering the 
markets. Thus, for the life-time analysis, the decision-analytic model needs to rely on 
surrogate parameters and efficacy extrapolation. However, this is a usual practice for 
economic analyses, and is also very common in the context of dialysis care where hard 
outcomes trials are very rare: Among eight previous studies reporting on the economics of 
SHPT treatment [13, 14, 20, 24, 25, 26, 27, 28] only two did not use surrogate parameters [13, 28]. 
However, as the treatment effect is an explicit input to our model, the model can easily be 
updated once alternative estimates become available. 
 
The efficacy estimates in this publication were based on the lag-censored approach. 
Though not in the context of cost-effectiveness analysis, the usage of lag-censored 
estimates has been questioned [29], and the ITT approach may be preferable, particularly to 
assess whether a drug has a treatment effect. In the context of economic analyses, however, 
the purpose is to provide a point estimate of cost-effectiveness. The ITT-based HRs are 
inconsistent with the model structure. Still, we found that compared to the ITT sensitivity 
analysis, the lag-censored estimates were more conservative. This is because the ITT-based 
HRs do not capture the complete spill-over effect post discontinuation. 
 
A limitation of the analysis is that the treatment effect does not vary by patient 
characteristics such as age. Assuming constant HRs over a wide range of potential 
subpopulation is a common approach in decision-analytic modelling, and is also often 
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assumed in meta-analyses. In the current case, we applied the published efficacy estimates 
based on the EVOLVE trial. No robust evidence exists that could be used to quantify a 
treatment effect by population subgroup. Furthermore, subgroup analyses also reduce the 
sample size, which makes it harder to detect significant differences. 
 
The current model was inspired by three previous cinacalcet cost-effectiveness models [13, 
14, 26]. Our definition of health states and the clinical events is generally consistent with 
these models. However, in the NICE PenTAG model [14] PTx affects PTH levels and thus 
indirectly the incidence of fractures and CV events. In our model, aligned with the other 
two analyses [13, 26] PTx only affects the estimation of costs and quality of life. As outlined 
below, this choice was based on the large uncertainty of PTx outcome data.  
 
Furthermore, in contrast to previous models, the etelcalcetide model explicitly simulates 
the discontinuation. This is important, as real-world studies on cinacalcet discontinuation 
have demonstrated that persistence is a key success factor of calcimimetic treatment. 
Based on the phase 3 trial data, we assumed the same persistence for both calcimimetics. In 
real world, however, due to the intravenous administration and potential improvements of 
gastrointestinal events, persistence may be better for etelcalcetide.  
 
In our illustration of this cost-effectiveness model, the third-party payer perspective was 
applied. For some settings, the considered corresponding costs may have limitations. In 
particular, for some settings, it may be relevant to also consider patients’ out-of-pocket 
costs or costs for administration.  
 
The presented model assigns equal probability of PTx to all possible transition states. A 
more complex model could have explicitly distinguished whether subjects can tolerate 
calcimimetic therapy, or it could have accounted for potential associations between the risk 
of fracture, CV events and PTx. Furthermore, a short-term utility decrement is accrued after 
PTx, but PTx has not been modelled to reduce risk of future complications and mortality. 
  Page 14 
 
Such decision rules, however, would not only have increased model complexity, but would 
also have required robust input data for quantification. Increasing model complexity 
beyond the level of available inputs does not increase the accuracy of the results, and a 
higher complexity often leads to criticism. The available data on consequences of PTx is 
very limited: No clinical trial exists that would compare the effectiveness of PTx vs. 
calcimimetics. Furthermore, PTx does not automatically lead to calcimimetics 
discontinuation [30].  
 
In this model we followed the established approach of not including dialysis costs [13, 31, 32, 
33]. Dialysis per se is not a cost-effective procedure and the inclusion of its high costs tends 
to drive the outcome of cost-effectiveness analyses so that even low-priced therapies might 
end up with high ICERs just because they are life-extending. 
 
The results of the presented cost-effectiveness analysis strongly depend on the price of the 
innovative drug. This is not uncommon, in particular if there are already alternative 
treatments on the market. However, it may be found difficult to conclude from the results 
which price for etelcalcetide would be appropriate. The purpose of this article, however, 
was not to make suggestions on which price would be reasonable, but was to present an 
economic model which can be adapted to various settings. In this context, we would also 
like to point out how substantial input parameters may differ from country to country. For 
example, in the US drug and event costs have been observed to be higher than in European 
settings [13, 26]. 
 
In conclusion, within the limits of the modelling approach, we created a model that could 
be used to assess the cost-effectiveness of etelcalcetide. The cost-effectiveness of 
etelcalcetide itself may depend on country settings, such as country specific prices, further 
model inputs, and willingness-to-pay. 
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TABLES 
Table 1 – Clinical input parameters 
Parameter Point 
estimate 
SE or [95%CI] Notes Sources 
Baseline event rates (events per person year) 
All-cause death   Age-specific annual 
mortality rates for 
dialysis patients 
with elevated levels 
of PTH, Ca, and P 
[20] 
   - 18-34 years old 0.045  
   - 35-44 years old 0.074  
   - 45-54 years old 0.094  
   - 55-64 years old 0.126  
   - 65-74 years old 0.165  
   - 75-84 years old 0.219  
   - 85+ years old 0.261  
Non-fatal CV   EVOLVE trial, 
analysis of patient-
level data 
EVOLVE 
   - first event 0.098 0.005 
   - subsequent event 0.620 0.047 
Non-fatal fracture   
   - first event 0.045 0.003 
   - subsequent event 0.114 0.024 
PTx 0.049 0.003 
HR clinical events, cinacalcet vs. placebo 
All-cause mortality 0.80 [0.69-0.91]  [13] 
CV events 0.78 [0.67-0.91] 
Fractures 0.73 [0.59-0.92] 
PTx 0.25 [0.19-0.33] 
HR clinical events, etelcalcetide vs. placebo 
All-cause mortality 0.75 [0.62-0.89]  [9, 10, 13] 
CV events 0.72 [0.59-0.88] 
Fractures 0.67 [0.50-0.89] 
PTx 0.17 [0.11-0.25] 
HR clinical events, etelcalcetide vs. cinacalcet 
All-cause mortality 0.94  [0.88,0.98]  [9, 10, 13] 
 CV events 0.93  [0.87,0.98] 
Fractures 0.91  [0.83,0.98] 
PTx 0.66  [0.51,0.81] 
Parametric functions to model the persistence of calcimimetics 
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Gamma parameter 0.459  Weibull function 
(time in months) 
[21] 
Lambda parameter 0.409  
HRQoL utilities 
Utility while on dialysis 0.71 0.013  [22] 
Absolute utility decrements     
   - CV event months 1-3 0.19 0.014 Aggregated among 
CV events 
[22] 
   - CV event after month 3 0.14 0.014 
   - fracture months 1-3 0.31 0.035  
   - fracture after month 3 0.12 0.020  
   - PTx months 1-3 0.06 0.020  
   - PTx after month 3 0 0 Assumption, based 
on non-significance 
(p=0.653) 
 
   - Calcimimetic treatment 0 0 Conservative 
assumption, as 
published point 
estimate implied a 
slight utility increase 
 
HR: hazard ratio; CV: cardiovascular; PTx: parathyroidectomy; SE: standard error; CI: confidence interval; na: not 
applicable 
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Table 2 – Input parameters on drug usage and costs 
Parameter Point 
estimate 
SE Sources 
Calcimimetic drug consumption (mg per day) 
Etelcalcetide 3.11 0.08 Efficacy assessment 
phase of etelcalcetide 
trials [9,10] 
Cinacalcet 64.18 2.78 
Vitamin D and/or analogs consumption (g per day) 
Alfacalcidol (oral) 0.07  0.005 Etelcalcetide trials 
[9,10]§ Alfacalcidol (IV) 0.009 0.002 
Calcitriol (oral) 0.05  0.003 
Calcitriol (IV) 0.006 0.0014 
Doxercalciferol (oral) 0.0005  0.00035 
Doxercalciferol (IV) 0.27  0.018 
Paricalcitol (oral) 0.02  0.005 
Paricalcitol (IV) 0.35  0.024 
Phosphate binders consumption (g per day) 
Aluminum containing 0.04  0.007 Etelcalcetide trials 
[9,10] § Calcium (Ca) containing 0.57  0.031 
Lanthanum carbonate 0.21  0.016 
Mg containing 0.03  0.005 
Mg and Ca containing 0.005  0.0023 
Sevelamer 1.73  0.058 
Unit costs (*) 
Cinacalcet (€/mg) € 0.218 n.a. Average of published 
cost data [24] CV event costs € 3,184 € 1,163 
Fracture event costs € 2,627 € 1,053 
PTx event costs € 4,249 € 2,097 
Monitoring costs (per quarter) € 72.9 € 4.8 [14] 
Vitamin D & phosphate binders Costs were set to zero for this illustrative analysis. 
Etelcalcetide Varies by scenario; results from the cinacalcet price 
via the dose ratio (multiplier) and a potential 
multiplier (1, 1.15, 1.3) to account for an increase in 
treatment costs 
CV: cardiovascular; PTx: parathyroidectomy; SE: standard error; CI: confidence interval; IV: intravenous; n.a., not 
applicable. 
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(*) Three price scenarios are explored for etelcalcetide: 1) same weekly calcimimetic drug cost – WCDC; 2) +15% WCDC 
and; 3) +30% WCDC. 
§ Safety analysis set, sum of cumulative doses divided by total exposure days; SE based on bootstrapping. 
 
 
  
  Page 24 
 
Table 3 - Base case results of the cost-effectiveness analysis 
 LYs QALYs Costs (discounted) 
 undiscounted discounted undiscounted discounted Same WCDC +15% WCDC +30% WCDC 
Etelcalcetide 7.575 6.348 4.749 4.032 €14,195 €14,932 €15,670 
Cinacalcet 7.520 6.304 4.771 4.000 €14,152 €14,152 €14,152 
Increments 
Etelcalcetide 
vs. 
cinacalcet 
0.055 0.043 0.039 0.032 €43 €780 €1,518 
ICER 
Etelcalcetide vs. cinacalcet €1,355/QALY €24,521/QALY €47,687/QALY 
QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio; LY: life-years; PB/VD: phosphate binders and vitamin D and/or analogs alone; 
WCDC: weekly calcimimetic drug cost. 
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Table 4 – Structural sensitivity analysis on the incremental cost-effectiveness ration 
ICER (€ per QALY) Same WCDC +15% WCDC +30% WCDC 
Base case 1,355 24,521 47,687 
No parathyroidectomy 1,727 24,915 48,103 
EVOLVE persistence 1,700 26,576 51,451 
16% one-year persistence 502 21,866 43,229 
Efficacy based on ITT 
disaggregation approach 
1,848 23,614 45,380 
QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio; WCDC: weekly calcimimetic drug cost; ITT, intention to treat. 
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FIGURES 
 
Figure 1 - Illustration of the decision-analytic model 
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Figure 2 – Results of the probabilistic sensitivity analysis of etelcalcetide vs. cinacalcet. A) cost-effectiveness 
acceptability curves; B) scatter plot of 1000 PSA iterations in the cost-effectiveness plane. WCDC: weekly 
calcimimetic drug cost; WTP: willingness to pay; QALY: quality-adjusted life-years. 
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Figure 3 – Tornado diagram on the impact on the incremental cost-effectiveness ratio 
(ICER), illustrated based on a cost increase of 15% of the weekly calcimimetic treatment 
costs. 
 
CV, cardiovascular; HR, hazard ratio; PTx, parathyroidectomy; Fx, fractures 
 
